- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03007615
Dermal and Gynecological Acceptability (Irritability and Sensitization in the Genital Mucosa) of an Investigational Product and Evaluation of Moisture Efficacy by TEWL and Perceived Efficacy. (DERM GYN ACCEP)
December 29, 2016 updated by: Kley Hertz S/A
To evaluate the safety of an investigational product through the verification of signs of irritability and sensitization of the genital mucosa, as well as the instrumental moisturizing efficacy by TEWL and barrier integrity analysis, in addition to the efficacy perceived by the volunteers.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
33
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Healthy female sex with active sex life;
- Age group: between 45 and 65 years old;
- Menopause for at least six months;
- Whole skin in the region of product analysis;
- No history of reaction to products of the same category
- Understanding, agreement and signature of the Term of Free and Informed Consent.
Exclusion Criteria:
- Gestation or risk of gestation;
- Use of anti-inflammatory / immunosuppressive drugs (in the last 30 days and during the study);
- Active cutaneous pathologies (local and / or disseminated) in the evaluation area;
- Pathologies that cause suppression of immunity, such as diabetes, HIV, etc.;
- Endocrine pathologies such as thyroid disorders, ovarian or adrenal gland disorders;
- Any infection in the region of analysis of the product diagnosed at the time of inclusion;
- Other conditions considered by the investigating physician as reasonable for disqualification of the individual from the study participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluation of the product's efficiency as a moisturizer through subjective evaluation
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2017
Primary Completion (Anticipated)
February 1, 2017
Study Registration Dates
First Submitted
December 29, 2016
First Submitted That Met QC Criteria
December 29, 2016
First Posted (Estimate)
January 2, 2017
Study Record Updates
Last Update Posted (Estimate)
January 2, 2017
Last Update Submitted That Met QC Criteria
December 29, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- Kley Hertz 007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Female Dry Genital Mucosa
-
Kley Hertz S/ACompleted
-
Kley Hertz S/ACompleted
-
Centre Hospitalier Universitaire de NiceTerminatedVulvar Intraepithelial Neoplasia | Vulvar Mucosa LesionsFrance
-
Piazza della Vittoria 14 Studio Medico - Ginecologia...CompletedFemale Genital Mutilation Type I Status | Female Genital Mutilation Type II Status | Female Genital Mutilation Type III StatusItaly
-
Arizona State UniversityCatholic Charities Phoenix; Phoenix International Refugee Committee; Refugee... and other collaboratorsCompletedFemale Genital Mutilation Type I Status | Female Genital Mutilation Type II Status | Female Genital Mutilation Type III StatusUnited States
-
Uppsala UniversityMalmö UniversityCompletedFemale Circumcision | Female Genital Mutilation/CuttingSweden
-
The University of Texas Medical Branch, GalvestonM.D. Anderson Cancer Center; The University of Texas Health Science Center,... and other collaboratorsActive, not recruitingMalignant Neoplasms of Female Genital OrgansUnited States
-
Northwestern UniversityCompletedMalignant Female Reproductive System NeoplasmUnited States
-
Assiut UniversityNot yet recruitingFemale Genital Mutilation
-
Genewel Co., LtdUnknownGenital Diseases, FemaleKorea, Republic of
Clinical Trials on Intimate Lubricant Gel
-
Kley Hertz S/ACompleted
-
Kley Hertz S/ACompleted
-
Kley Hertz S/ACompleted
-
Herbarium Laboratorio Botanico LtdaCompletedVaginal Diseases | Atrophic VaginitisBrazil
-
Alcon ResearchCompletedDry EyeAustralia, Canada
-
Johnson & Johnson Consumer and Personal Products...Completed
-
Kley Hertz S/AUnknown
-
Alcon ResearchCompleted
-
Church & Dwight Company, Inc.CompletedCumulative IrritationUnited States